See the DrugPatentWatch profile for vascepa

To gather information for Vascepa (icosapent ethyl) coverage, you may consider the following papers and resources:

1. BMJ Evidence-Based Medicine. (2020). Icosapent ethyl for the prevention of cardiovascular events: a systematic review and meta-analysis. <https://ebm.bmj.com/content/25/1/33>

2. American Journal of Cardiology. (2019). Icosapent Ethyl for Very High Triglycerides. <https://www.ajconline.org/content/73/10/1429>

3. Journal of Clinical Lipidology. (2019). Icosapent Ethyl for the Treatment of Statin-Treated Patients with Persistent High Triglycerides. <https://www.sciencedirect.com/science/article/pii/S1933287419303453>

4. Cardiovascular Therapeutics. (2018). Icosapent Ethyl for the Reduction of Cardiovascular Events in Statin-Treated Patients with Persistent High Triglycerides. <https://journals.lww.com/cardiologyinreview/Abstract/2018/12000/Icosapent_Ethyl_for_the_Reduction_of_Cardiovascular.2.aspx>

5. DrugPatentWatch.com. (n.d.). Vascepa (icosapent ethyl) Patent & Drug Profile. <https://www.drugpatentwatch.com/drugs/vascepa>

These sources provide information on Vascepa's clinical effectiveness, its role in treating patients with persistent high triglycerides, and its patent and drug profile. By reviewing these papers, you can gather a comprehensive understanding of Vascepa and its implications for coverage.

Sources:

[1] <https://ebm.bmj.com/content/25/1/33>
[2] <https://www.ajconline.org/content/73/10/1429>
[3] <https://www.sciencedirect.com/science/article/pii/S1933287419303453>
[4] <https://journals.lww.com/cardiologyinreview/Abstract/2018/12000/Icosapent_Ethyl_for_the_Reduction_of_Cardiovascular.2.aspx>
[5] <https://www.drugpatentwatch.com/drugs/vascepa>